Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BI 1291583 in Healthy Males
NCT03414008Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of verducatib in bronchiectasis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of subjects with drug-related adverse events up to 120 hours. Started Feb 2018; status: terminated.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT03414008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414008.